Ophthalmic Business News

LumiThera submitted a de novo request to the FDA to reclassify the Valeda light delivery system as a Class II device for the treatment of dry age-related macular degeneration, according to a press release.

When choosing a structure for a practice, you are making two choices: what legal structure to choose and which tax treatment to select.

The Residency to Retirement resource center offers insightful and innovative strategies to help physicians reduce taxes, protect assets, invest wisely and build wealth during all phases of their careers.

Five Medicare Administrative Contractors have withdrawn their final local coverage determinations for micro-invasive glaucoma surgery that were scheduled to take effect on Jan. 29, 2024, according to a press release from Sight Sciences.

Healio’s top ophthalmic business-related items in 2023 covered the changing landscape of determining prices for drugs in the U.S. and the recall of generic artificial tears.

The FDA granted orphan drug designation for Cellusion’s CLS001, a corneal endothelial cell substitute for bullous keratopathy, according to a press release.

I read with great interest the blog “Avastin W” by John A. Hovanesian, whom I would like to congratulate for touching on a delicate argument that affects the quality of life of individuals affected by macular and retinal diseases.

Nordic Pharma has acquired Visant Medical through its subsidiary Amring Pharmaceuticals.

SAN FRANCISCO — Ophthalmologists can reduce unnecessary waste by changing the way they use topical drops, according to a speaker at the American Academy of Ophthalmology meeting.

Carl Zeiss Meditec AG has entered into an agreement to acquire all shares of Dutch Ophthalmic Research Center, according to a press release.